Thinking up tomorrow's medicine
[Press release] Valneva, a leading pure play vaccines biotech company, announced today that it has signed a n exclusive license agreement with the Chinese company Jianshun Biosciences Ltd to commercialize Valneva’s EB66® cell line for the manufacturing of human and veterinary vaccines in People’s Republic of China only.
[press release] Valneva, a leading pure play vaccines biotech company, announced that it has signed a new research license agreement with Merial and a commercial license agreement with an undisclosed European company to develop veterinary vaccines using Valneva’s EB66 ® vaccine cell line platform. Valneva is member of Atlanpole Biotherapies.
The young company aims at becoming a European leader in gene therapy for the treatment of rare genetic diseases in ophthalmology for which no treatment exists to date. The company has launched the development of a medicine intended to treat a form of retinitis pigmentosa. This is possible thanks to the confidence of private investors and of the Public Investment Bank (BPIfrance), which will ensure its operation until the end 2015. Member of Atlanpole Biotherapies, Horama is also supported by IHU Cesti (European Center for Transplantation and Immunotherapy Sciences).
New member: Amadéite, a company of the Olmix Group, values the properties of algae in the human diet
The Olmix group, based in Bréhan is a pioneer of marine algae exploitation. Its Amadéite SAS subsidiary was created in 2011 to manage all the R & D group activities and to develop its expertise (for the complete managment of the R & D group activities and the developement of its expertise) in the blue biotechnology towards the "human care" sector.
Meet them there.
Alongside BIO 2015, come and meet the companies members of our cluster experts in oncology during this event. Participation is free, sign up now to attend your place.
Research, Cancer, Ethics Bioinformatics, Plant science Mitochondrial medicine... Share your knowledge with international researchers and students from different countries and cultures.
The CMSB 2015 conference will be held in Nantes from Sept. 16th to Sept. 18th. The conference brings together computer scientists, biologists, mathematicians, engineers and physicists interested in a system-level understanding of biological processes.
The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation.
Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005).